A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

March 6, 2026 updated by: Hansoh BioMedical R&D Company

A Multicenter, Randomized, Open-Label, Controlled Phase III Clinical Study Evaluating the Efficacy and Safety of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

This is a multicenter, randomized, open-label, controlled phase III clinical study to evaluate the efficacy and safety of HS-20093 injection combined with adebrelimab versus docetaxel in previously treated patients with advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a multicenter, randomized, open-label, controlled phase III clinical study to evaluate the efficacy and safety of HS-20093 injection combined with adebrelimab versus docetaxel in previously treated patients with advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.

Eligible participants will be randomly assigned in a 1:1 ratio to the experimental arm (HS-20093 and adebrelimab) or the control arm (docetaxel injection). Participants in the experimental arm will receive intravenous infusions of HS-20093 and adebrelimab: HS-20093 at a dose of 8.0 mg/kg every 3 weeks (Q3W) until disease progression or other treatment discontinuation criteria are met; adebrelimab at a dose of 1200 mg Q3W until disease progression or other treatment discontinuation criteria are met. Participants in the control arm will receive docetaxel at a dose of 75 mg/m² Q3W until disease progression or other treatment discontinuation criteria are met. Efficacy and safety will be analyzed and evaluated in both arms following the protocol-specified follow-up procedures.

Study Type

Interventional

Enrollment (Estimated)

450

Phase

  • Phase 3

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Age ≥18 years at the time of informed consent form (ICF) signature, either sex.
  2. Be willing to participate in this clinical trial with understanding of study procedures, ability to provide written informed consent, and commitment to comply with all requirements specified in this clinical trial protocol.
  3. Previously treated patients with histologically or cytologically confirmed diagnosis of advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC).
  4. Presence of at least one measurable target lesion.
  5. Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 to 1.
  6. Minimum life expectancy >12 weeks.
  7. Adequate organ function.
  8. Absence of the following active infectious diseases: hepatitis B, hepatitis C, human immunodeficiency virus (HIV) infection, tuberculosis, or syphilis.
  9. Female participants with negative serum pregnancy test result within 7 days prior to first dose administration, or documentation of no pregnancy risk.

Exclusion Criteria:

  1. Prior pathological diagnosis of mixed non-small cell lung cancer or any transformed non-small cell lung cancer.

  2. Prior or ongoing treatment with any of the following:

    1. Prior or current treatment targeting B7-H3;
    2. Prior or current treatment with topoisomerase I inhibitor agents, including antibody-drug conjugates with topoisomerase I inhibitor payloads, etc.;
    3. Prior treatment with docetaxel monotherapy or in combination with other agents.
  3. Persistent adverse reactions caused by prior treatment.
  4. Untreated brain metastases; uncontrolled brain metastases; presence of leptomeningeal or brainstem metastases; presence of spinal cord compression (identified by radiographic imaging, regardless of symptoms).
  5. History of other primary malignancies.

  6. Presence of any of the following abnormal cardiac findings:

    1. Evidence of currently clinically significant important arrhythmia or ECG abnormality;
    2. Presence of risk factors causing QT interval prolongation or arrhythmic events.
  7. Severe, uncontrolled, or active cardiovascular or cerebrovascular disease.
  8. Severe or poorly controlled hypertension.
  9. Severe or poorly controlled diabetes mellitus.
  10. Clinically significant bleeding symptoms or significant bleeding tendency.
  11. Severe infection.
  12. History of severe arterial or venous thromboembolic events.
  13. Known or suspected interstitial pneumonitis, immune-mediated pneumonitis, or radiation pneumonitis.
  14. Participants with active or history of autoimmune disease with potential for recurrence.
  15. Prior occurrence of severe or life-threatening immune-mediated adverse events.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Docetaxel
Drug: Docetaxel
Participants will receive docetaxel at a dose of 75 mg/m² Q3W until disease progression or other treatment discontinuation criteria are met.
Experimental: HS-20093 and adebrelimab
Drug: HS-20093
Participants will receive intravenous infusions of HS-20093 and adebrelimab: HS-20093 at a dose of 8.0 mg/kg every 3 weeks (Q3W) until disease progression or other treatment discontinuation criteria are met; adebrelimab at a dose of 1200 mg Q3W until disease progression or other treatment discontinuation criteria are met.
Other Names:
  • GSK5764227
  • Risvutatug Rezetecan

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR)
Time Frame: Approximately 3 years after the fist patient with first dose
Progression-free survival (PFS) assessed by BICR per RECIST v1.1.
Approximately 3 years after the fist patient with first dose
Overall survival (OS)
Time Frame: Approximately 5 years after the fist patient with first dose
Overall Survival is defined as the time from the date of randomization to the date of participant's death due to any cause.
Approximately 5 years after the fist patient with first dose

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PFS assessed by investigator
Time Frame: Approximately 3 years after the fist patient with first dose
PFS assessed by investigator per RECIST v1.1
Approximately 3 years after the fist patient with first dose
Objective response rate (ORR)
Time Frame: Approximately 3 years after the fist patient with first dose
Objective response rate (ORR) assessed by BICR and investigator per RECIST v1.1
Approximately 3 years after the fist patient with first dose
Disease control rate (DCR)
Time Frame: Approximately 3 years after the fist patient with first dose
Disease control rate (DCR) assessed by BICR and investigator per RECIST v1.1
Approximately 3 years after the fist patient with first dose
Duration of response (DoR)
Time Frame: Approximately 3 years after the fist patient with first dose
Duration of response (DoR) assessed by BICR and investigator per RECIST v1.1
Approximately 3 years after the fist patient with first dose
Incidence and severity of AEs
Time Frame: From the first dose until 90 days after the last dose
From the first dose until 90 days after the last dose
Incidence and severity of SAEs
Time Frame: From the first dose until 90 days after the last dose
From the first dose until 90 days after the last dose

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hansoh BioMedical R&D Company

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 31, 2026

Primary Completion (Estimated)

December 31, 2028

Study Completion (Estimated)

December 31, 2029

Study Registration Dates

First Submitted

March 6, 2026

First Submitted That Met QC Criteria

March 6, 2026

First Posted (Actual)

March 11, 2026

Study Record Updates

Last Update Posted (Actual)

March 11, 2026

Last Update Submitted That Met QC Criteria

March 6, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HS-20093-309

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Non-Small Cell Lung Cancer

Clinical Trials on HS-20093

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe